Active Clinical Trials

Laser Ablation of Abnormal Neurological TissuE Using Robotic NeuroBlate® System (LAANTERN) Prospective Multi‑Center Registry

Study Overview:

LAANTERN is a prospective, multi-center registry that will include data collection up to 5 years to evaluate safety, Quality of Life (QoL), and procedural outcomes including local control failure rate, progression free survival, overall survival, and seizure freedom in up to 1,000 patients and up to 50 sites. The study is currently enrolling eligible patients who would like to participate.

Study Device and Procedure:

The LAANTERN Registry will use the NeuroBlate System, a minimally invasive robotic laser thermotherapy tool that uses MRI-guided laser energy to ablate brain lesions.

With NeuroBlate, the surgeon attempts to ablate (destroy) lesions, or abnormal tissue, in the brain.  Unlike traditional brain surgery, a procedure with the NeuroBlate System does not require a large opening in the skull.  Instead, doctors create a small hole in the skull, about the diameter of a pencil.  While the patient is in the MRI machine, the doctor guides a small laser device (probe) through the hole into the lesion.  The probe delivers laser light energy that heats and destroys the affected tissue.  Because the NeuroBlate System is MRI-guided, the neurosurgeon is able to visualize the specific area of the brain to be ablated.  The precise nature of the procedure helps to lessen the likelihood of harm to nearby healthy tissue.1

Study Eligibility:

You may qualify to participate in this study if you are planning to undergo the NeuroBlate procedure.

You may be a candidate if:

  • You are undergoing thermal therapy with the NeuroBlate System.
  • You provide written authorization and/or consent per requirements.
  • You are available for the required study follow-up.

To take the next step, please contact a study center for more information. Only a study doctor can decide if you are a candidate for the study.

Study Purpose and Follow-up:

This Registry is intended to further understand the performance and utilization of the NeuroBlate System in current standard of care and will collect baseline, procedural and follow-up data. If you qualify for the study and you decide to participate, you will be provided with questionnaires to complete after your procedure and you will have more contact with hospital staff regarding your well-being. Visits to the clinic will be done on an as-needed basis and as recommended by your doctor.

Find a Study Center:


Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital & Medical Center
Phoenix, AZ
Site Principal Investigator: Kris Smith, MD
Contact: Odilette Trevizo, RN, CNRN


University of Arkansas for Medical Sciences
Little Rock, AR
Site Principal Investigator: Analiz Rodriguez, MD
Contact: Sorena Lo


University of California, San Diego
La Jolla, CA
Site Principal Investigator: David Piccioni, MD
Contact: Lara Rose

Children’s Hospital of Orange County
Orange, CA
Site Principal Investigator: Joffre Olaya, MD
Contact: Anthony Vargas, BS


Yale University School of Medicine
New Haven, CT
Site Principal Investigator: Veronica Chiang, MD
Contact: Judith Hess


Advent Health Orlando
Orlando, FL
Site Principal Investigator: James Baumgartner, MD
Contact: Brooke Hartwell

Cleveland Clinic Weston
Weston, FL
Site Principal Investigator: Hamid Borghei-Razavi, MD
Contact: Lilian Cadet


Northwestern University
Chicago, IL
Site Principal Investigator: S. Kathleen Bandt, MD
Contact: Ashkan Zarrieneh


University of Kansas Medical Center
Kansas City, KS
Site Principal Investigator: Patrick Landazuri, MD
Contact: Lauren Holland


University of Louisville
Louisville, KY
Site Principal Investigator: Joseph Neimat, MD
Contact: Anna Williford

Norton Cancer Institute
Louisville, KY
Site Principal Investigator: David Sun, MD
Contact: Debbie Cobb


University of Minnesota
Minneapolis, MN
Site Principal Investigator: Clark Chen, MD
Contact: Clark Chen, MD

Children’s Hospital St. Paul
St. Paul, MN
Site Principal Investigator: Joseph Petronio, MD
Contact: Katherine Ingram


Washington University
Saint Louis, MO
Site Principal Investigator: Albert Kim, MD
Contact: Robin Haverman

New York

New York University Langone Medical Center
New York, NY
Site Principal Investigator: Sylvia Kurz, MD
Contact 1: Malcolm Delara
Contact 2: Ankeeta Joshi

Icahn School of Medicine at Mount Sinai
New York, NY
Site Principal Investigator: Constantino Hadjipanayis, MD
Contact: Armand Harb

SUNY Upstate Medical University
Syracuse, NY
Site Principal Investigator: Zulma Tovar-Spinoza, MD
Contact: Sean Huckins

North Carolina

Duke University Medical Center
Durham, NC
Site Principal Investigator: Peter Fecci, MD
Contact: Courtney Wimberly

Wake Forest
Winston-Salem, NC
Site Principal Investigator: Stephen Tatter, MD
Contact: Kimberly Hawley


University Hospitals Cleveland Medical Center
Cleveland, OH
Site Principal Investigator: Andrew Sloan, MD
Contact: Karen Devine

Cleveland Clinic Foundation
Cleveland, OH
Site Principal Investigator: Alireza Mohammadi, MD
Contact: Teresa Allison


Geisinger Medical Center
Danville, PA
State Principal Investigator: Michel Lacroix, MD
Contact: Chelsie Derr

University of Pittsburgh Medical Center
Pittsburgh, PA
Site Principal Investigator: Taylor Abel, MD
Contact: Madison Remick


Saint Thomas West Hospital and Research Institute
Nashville, TN
Site Primary Investigator: Steven Abram, MD
Contact: Margaret Serfass


MD Anderson
Houston, TX
Site Principal Investigator: Sujit Prabhu, MD
Contact: Carmen Jacobs

University of Texas Southwestern Medical Center
Dallas, TX
Site Principal Investigator – Kalil Abdullah, MD
Contact: Hayyan Yousuf

Monteris Medical Announces Publication of First Prospective Multicenter Study of Minimally Invasive Laser Ablation for Drug Resistant Epilepsy

Monteris Medical Announces Favorable 12-Month Outcomes for Patients Receiving Minimally Invasive Laser Ablation for Brain Tumors

Study Suggests Potential Role for Laser Ablation in Glioblastoma Treatment, Monteris Medical Announces

Monteris Medical Reaches Milestone of 3,000 Patients with NeuroBlate® System


Monteris provides technology for neurosurgeons, which allows them to ablate (destroy with heat), brain structures such as brain tumors, radiation necrosis, and epileptic foci. Monteris technology includes the NeuroBlate System, AtamA, and MiniBolt devices, which may be used together to apply the focused laser energy with little or no effect on surrounding healthy tissue. The NeuroBlate System provides clinicians a tool that offers near real-time control and MRI visualization of the therapy during laser ablation treatment.

All brain surgeries carry risk. Possible adverse events include, but are not limited to, hematoma, embolic events, edema, bleeding, cerebral spinal fluid (CSF) leakage, infection, unintended major tissue damage and permanent neurological deficits. Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.

Rx Only.

1. Rennert RC, Khan U, Bartek J, et al. Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization. Neurosurgery. May 2019. doi:10.1093/neuros/nyz141